Last reviewed 2026-04-19 · How we verify

Infectious disease of abdomen

Approved treatments

• MEZLOCILLIN
• Ramycin
  Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins.
• Garamycin · Merck & Co.
• Eryped · Arbor Pharms Llc
• Doribax · Shionogi
• Tygacil · Fresenius Kabi
  Tygacil works by binding to the 30S ribosomal subunit of bacteria, preventing the aminoacyl-tRNA from binding and thereby inhibiting protein synthesis.
• Cleocin T · Pfizer
  Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.
• Maxipime · Baxter
  Cefepime is a cephalosporin antibacterial drug.
• Xerava · Tetraphase Pharms
  Xerava works by binding to the bacterial ribosome, preventing the synthesis of essential proteins necessary for bacterial survival.
• Claforan · Sterimax
• Unasyn · Bristol-Myers Squibb
• Cleocin · Generic (originally Upjohn/Pfizer)
  Lincosamide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with excellent anaerobic coverage.
• Avelox · Bayer AG
  Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms.
• Abelcet · Astellas Pharma
• Unasyn · Pfizer
• Metro I.V. In Plastic Container · Baxter
• Maxipime · Baxter
  Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis.
• Pipracil
  Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death.
• Cefepim · University Hospital Tuebingen
• Ciprofloxacine · Poitiers University Hospital
• Gentamicin · Merck & Co.
• Tygacil · Pfizer
  Tigecycline is a tetracycline class antibacterial agent.
• Cefadole
  Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• ALATROFLOXACIN · Pfizer
• Avelox · Novartis Pharmaceuticals
• Ceftriaxon · Centre Hospitalier Universitaire Vaudois
• Avycaz · Cerexa Inc
  EMBLAVEO is an antibacterial drug.
• Merrem · National Institutes of Health Clinical Center (CC)
• Azactam · Bristol-Myers Squibb
  Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent.
• Invanz · Merck & Co.
  Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Primaxin · Merck Sharp & Dohme B.V.
  Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Zerbaxa · Cubist Pharms
  Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Arikayce Kit · Bristol-Myers Squibb
  Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.
• Fortaz · Pai Holdings Pharm
  Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death.
• Mefoxin In Sodium Chloride 0.9% In Plastic Container
• Merrem · Pfizer
  Meropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Cefotan
• Primaxin · Merck & Co.
  Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body.
• Recarbrio · Merck & Co.
  Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria.
• TICARCILLIN
• Ticarcillin
• Kanacin · Bristol-Myers Squibb
• Fortaz · Pai Holdings Pharm
  Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance.
• Noroxin
• Floxin
• Epocelin
• Zefazone
• Cipro · Bayer AG
• Rocephin · Generic (originally Roche)
• Ceftazidim · Tel-Aviv Sourasky Medical Center

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Infectious disease of abdomen patent landscape — cliff calendar, originator estates, attackable patents
• Infectious disease of abdomen treatment landscape brief
• Infectious disease of abdomen treatment updates RSS

Frequently asked questions about Infectious disease of abdomen

Related

• Treatment landscape: Infectious disease of abdomen patent cliff · Infectious disease of abdomen CI report
• Treatment: MEZLOCILLIN
• Treatment: Ramycin
• Treatment: Garamycin · Merck & Co.
• Treatment: Eryped · Arbor Pharms Llc
• Treatment: Doribax · Shionogi
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing